Treatment of Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in Clinical Practice.

doi:10.21873/anticanres.14592

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Treatment of Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in Clinical Practice.

Anticancer research - 1 Oct 2020

Yamada Yutaka, Tamura Tomohiro, Yamamoto Yusuke, Ichimura Hideo, Hayashihara Kenji, Saito Takefumi, Yamada Hideyasu, Endo Takeo, Nakamura Ryota, Inage Yoshihisa, Satoh Hiroaki, Iguchi Kesato, Saito Kazuto, Inagaki Masaharu, Kikuchi Norihiro, Kurishima Koichi, Ishikawa Hiroichi, Sakai Mitsuaki, Kamiyama Koichi, Shiozawa Toshihiro, Hizawa Nobuyuki, Sekine Ikuo, Sato Yukio, Funayama Yasunori, Miyazaki Kunihiko, Kodama Takahide, Hayashi Shigen, Nomura Akihiro, Nakamura Hiroyuki, Furukawa Kinya, Yamashita Takaaki, Okubo Hatsumi, Suzuki Hisashi, Kiyoshima Moriyuki, Kaburagi Takayuki

Abstract excerpt

BACKGROUND/AIM: To describe real clinical outcomes in patients with non-small cell lung cancer who have uncommon epidermal growth factor receptor (EGFR) mutations. MATERIALS AND METHODS: We performed a retrospective chart review from 15 medical institutes that cover a population of three million people from April 2008 to March 2019. RESULTS: There were 102 patients with uncommon EGFR mutation. Progression-free...

Topics

Acrylamides
Adult
Afatinib
Aged
Aged, 80 and over
Aniline Compounds
Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Cell Proliferation

ErbB Receptors

Erlotinib Hydrochloride

Female

Gefitinib

Humans

Male

Middle Aged

Mutation

Progression-Free Survival

Protein Kinase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 32988903
DOI: 10.21873/anticanres.14592

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in Clinical Practice.PMID 32988903Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.Semantic proximity Read ↗

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief ReportSemantic proximity Read ↗

Outcomes of Afatinib in Non-small Cell Lung Cancer Patients Harboring Uncommon Epidermal Growth Factor Receptor MutationsSemantic proximity Read ↗

From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.Semantic proximity Read ↗

Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation.Semantic proximity Read ↗

Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study.Semantic proximity Read ↗

Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study.Semantic proximity Read ↗

First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.Semantic proximity Read ↗

Real-world Outcomes of First-line Afatinib in Patients with Non-small Cell Lung Cancer and Uncommon EGFR Mutations in South KoreaSemantic proximity Read ↗

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations.Semantic proximity Read ↗

Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.